Karim M, Chowdhury E
J Funct Biomater. 2022; 13(4).
PMID: 36412852
PMC: 9680366.
DOI: 10.3390/jfb13040211.
Pinet L, Assrir N, van Heijenoort C
Biomolecules. 2021; 11(11).
PMID: 34827688
PMC: 8615588.
DOI: 10.3390/biom11111690.
Comparan-Meza M, Vargas de la Cruz I, Jauregui-Huerta F, Gonzalez-Castaneda R, Gonzalez-Perez O, Galvez-Contreras A
Brain Behav. 2021; 11(10):e2341.
PMID: 34472728
PMC: 8553330.
DOI: 10.1002/brb3.2341.
Flier J, Kahn C
Mol Metab. 2021; 52:101194.
PMID: 33610859
PMC: 8513142.
DOI: 10.1016/j.molmet.2021.101194.
Choi B, Cha M, Eun G, Lee D, Lee S, Ehsan M
Elife. 2020; 9.
PMID: 32267234
PMC: 7176432.
DOI: 10.7554/eLife.53934.
Rethink of EGFR in Cancer With Its Kinase Independent Function on Board.
Thomas R, Weihua Z
Front Oncol. 2019; 9:800.
PMID: 31508364
PMC: 6716122.
DOI: 10.3389/fonc.2019.00800.
A Chimeric Egfr Protein Reporter Mouse Reveals Egfr Localization and Trafficking In Vivo.
Yang Y, Ma H, Starchenko A, Huh W, Li W, Hickman F
Cell Rep. 2017; 19(6):1257-1267.
PMID: 28494873
PMC: 5517093.
DOI: 10.1016/j.celrep.2017.04.048.
The paradoxical functions of EGFR during breast cancer progression.
Ali R, Wendt M
Signal Transduct Target Ther. 2017; 2.
PMID: 28435746
PMC: 5397119.
DOI: 10.1038/sigtrans.2016.42.
ErbB Proteins as Molecular Target of Dietary Phytochemicals in Malignant Diseases.
Filippi A, Ciolac O, Ganea C, Mocanu M
J Oncol. 2017; 2017:1532534.
PMID: 28286519
PMC: 5327764.
DOI: 10.1155/2017/1532534.
mTOR regulates proteasomal degradation and Dp1/E2F1- mediated transcription of KPNA2 in lung cancer cells.
Wang C, Chen Y, Wang C, Yu J, Chang Y, Yu C
Oncotarget. 2016; 7(18):25432-42.
PMID: 27009856
PMC: 5041915.
DOI: 10.18632/oncotarget.8170.
Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3.
Gaborit N, Lindzen M, Yarden Y
Hum Vaccin Immunother. 2015; 12(3):576-92.
PMID: 26529100
PMC: 4964743.
DOI: 10.1080/21645515.2015.1102809.
Proteomics in cancer biomarkers discovery: challenges and applications.
Sallam R
Dis Markers. 2015; 2015:321370.
PMID: 25999657
PMC: 4427011.
DOI: 10.1155/2015/321370.
Epidermal growth factor receptor (EGFR) signaling requires a specific endoplasmic reticulum thioredoxin for the post-translational control of receptor presentation to the cell surface.
Dong A, Wodziak D, Lowe A
J Biol Chem. 2015; 290(13):8016-27.
PMID: 25666625
PMC: 4375459.
DOI: 10.1074/jbc.M114.623207.
The adaptor proteins p66Shc and Grb2 regulate the activation of the GTPases ARF1 and ARF6 in invasive breast cancer cells.
Haines E, Saucier C, Claing A
J Biol Chem. 2014; 289(9):5687-703.
PMID: 24407288
PMC: 3937643.
DOI: 10.1074/jbc.M113.516047.
The ERBB network: at last, cancer therapy meets systems biology.
Yarden Y, Pines G
Nat Rev Cancer. 2012; 12(8):553-63.
PMID: 22785351
DOI: 10.1038/nrc3309.
STAT1 gene expression is enhanced by nuclear EGFR and HER2 via cooperation with STAT3.
Han W, Carpenter R, Cao X, Lo H
Mol Carcinog. 2012; 52(12):959-69.
PMID: 22693070
PMC: 3482422.
DOI: 10.1002/mc.21936.
Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations.
Han W, Lo H
Cancer Lett. 2012; 318(2):124-34.
PMID: 22261334
PMC: 3304012.
DOI: 10.1016/j.canlet.2012.01.011.
EGFR and EGFRvIII undergo stress- and EGFR kinase inhibitor-induced mitochondrial translocalization: a potential mechanism of EGFR-driven antagonism of apoptosis.
Cao X, Zhu H, Ali-Osman F, Lo H
Mol Cancer. 2011; 10:26.
PMID: 21388543
PMC: 3063231.
DOI: 10.1186/1476-4598-10-26.
Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations.
Wykosky J, Fenton T, Furnari F, Cavenee W
Chin J Cancer. 2011; 30(1):5-12.
PMID: 21192840
PMC: 3359794.
DOI: 10.5732/cjc.010.10542.
Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer.
Ranjan Patra C, Bhattacharya R, Mukhopadhyay D, Mukherjee P
Adv Drug Deliv Rev. 2009; 62(3):346-61.
PMID: 19914317
PMC: 2827658.
DOI: 10.1016/j.addr.2009.11.007.